(Q40345895)

19 September 2017

title

Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice (English)

1 reference

19 September 2017

0 references

hepatocellular carcinoma

1 reference

Hong Ma

1

1 reference

19 September 2017

Yanxin Liu

2

1 reference

19 September 2017

Shilian Liu

3

1 reference

19 September 2017

Ruian Xu

4

1 reference

19 September 2017

Dexian Zheng

5

1 reference

19 September 2017

language of work or name

English

0 references

publication date

1 December 2005

1 reference

19 September 2017

1 reference

19 September 2017

volume

42

1 reference

19 September 2017

issue

6

1 reference

19 September 2017

page(s)

1355-1363

1 reference

Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis

19 September 2017

cites work

1 reference

Fiber-modified adenoviral vector expressing the tumor necrosis factor-related apoptosis-inducing ligand gene from the human telomerase reverse transcriptase promoter induces apoptosis in human hepatocellular carcinoma cells

21 January 2018

1 reference

Safety and antitumor activity of recombinant soluble Apo2 ligand

21 January 2018

1 reference

7 January 2021

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

1 reference

7 January 2021

Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL.

1 reference

7 January 2021

Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector

1 reference

7 January 2021

Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus

1 reference

7 January 2021

Recombinant adeno-associated virus-mediated TRAIL gene therapy suppresses liver metastatic tumors

1 reference

7 January 2021

Peroral gene therapy of lactose intolerance using an adeno-associated virus vector

1 reference

7 January 2021

CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice

1 reference

7 January 2021

Long-term expression of angiostatin suppresses metastatic liver cancer in mice

1 reference

7 January 2021

AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumor regression.

1 reference

7 January 2021

TRAIL and its receptors as targets for cancer therapy

1 reference

7 January 2021

Tissue distribution of the death ligand TRAIL and its receptors.

1 reference

7 January 2021

Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines

1 reference

7 January 2021

Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma

1 reference

7 January 2021

Expression of TNF-related apoptosis-inducing Ligand receptors and antitumor tumor effects of TNF-related apoptosis-inducing Ligand in human hepatocellular carcinoma

1 reference

7 January 2021

Adenovirus-mediated gene transfer to orthotopic hepatocellular carcinomas in athymic nude mice

1 reference

7 January 2021

Barriers to drug delivery in solid tumors

1 reference

7 January 2021

Electroporation-mediated tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L gene therapy for hepatocellular carcinoma.

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.20918

1 reference

19 September 2017

1 reference